Metaphors in Nanomedicine: The Case of Targeted Drug Delivery

NanoEthics

Volumn 8, Issue 1, 2014, Pages 1-17

  Bensaude Vincent, Bernadette ^a,b,c   Loeve, Sacha ^a,b  

^a CETCOPRA   (France)

^b UNIVERSITÉ PARIS 1 PANTHÉON SORBONNE   (France)

^c IUF   (France)

Author keywords

Affordances; Dispositions; Efficacy; Efficiency; Magic bullet; Nanomedicine; Nanorobot; Pharmacology

Indexed keywords

EID: 84897451399     PISSN: 18714757     EISSN: 18714765     Source Type: Journal    
DOI: 10.1007/s11569-013-0183-5     Document Type: Article

References (101)

1. Annas G (1995) Reframing the debate on health care reform by replacing our metaphors. N Engl J Med 332: 744-747.
2. Arrigo BA (1999) Martial metaphors and medical justice: implications for law, crime, and deviance. J Polit Mil Soc 27: 307-322.
3. Austin JL (1962) How to do things with words. Clarendon, Oxford.
4. Bawa R (2008) Nanoparticle-based therapeutics in humans: a survey. Nanotechnol Law Bus 5: 135-155.
5. Bensaude-Vincent B, Guchet X (2007) Nanomachine: One Word for Three Different Paradigms. Technè 11: 71-89.
6. Bhattacharya S (2003) Gold "nano-bullets" shoot down tumours. New Scientist. Retrieved August 20, 2012, from http://www. newscientist. com/article/dn4341-gold-nanobullets-shoot-down-tumours. html.
7. Boenink M (2009) Tensions and opportunities in convergence: shifting concepts of disease in emerging molecular medicine. Nanoethics 3: 243-255.
8. Caroll SP (2011) Conciliation biology: the eco-evolutionary management of permanently invaded biotic systems. Evol Appl 4: 184-199.
9. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7: 383-388.
10. Cheng Z, Zaki AA, Hui JZ, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338: 903-910.
11. Chess R (1998) Economics of drug delivery. Pharm Res 15: 172-174.
12. Choi C (2009) Magic nano-bullets: advances in nanotechnology could make drug delivery far more accurate and effective. Sci Am/World View. Retrieved August 20, 2012 from http://www. saworldview. com/article/magic-nano-bullets.
13. Choi WI, Kim JY, Kang C, Byeon CC, Kim YH, Tae G (2011) Tumor regression in vivo by photothermal therapy based on gold-nanorod-loaded, functional nanocarriers. ACS Nano 5: 1995-2003.
14. Couvreur P (2009) Super Vector!, Revue pour l'histoire du CNRS, 24. Retrieved February 10, 2012 from http://histoire-cnrs. revues. org/9061.
15. Couvreur P (2010) Interview by Xavier Guchet, Sacha Loeve & Nicolas Sauret, Faculté de pharmacie de Chatenay-Malabry, 30 November 2010.
16. Couvreur P, Kante B, Grislain L, Roland M, Speiser P (1982) Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J Pharm Sci 71: 1520-6017.
17. Couvreur P, Tulkens P, Roland M, Trouet A, Speiser P (1977) Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett 84: 323-326.
18. Couvreur P, Vauthier C (2006) Nanotechnology. Intelligent design to treat complex disease. Pharm Res 23: 1417-1450.
19. Crawford LM (2004) Remarks by Lester M. Crawford, D. V. M., Ph. D., Acting Commissioner of the FDA, before PhRMA Annual Meeting. Retrieved February 10, 2012, from http://www. fda. gov/NewsEvents/Speeches/ucm053576. htm.
20. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke JPM, Schroeder TV, Sox HC, van Der Weyden MB (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. J Am Med Assoc 1671: 137-141.
21. Debus AG (1991) The French Paracelsians. the chemical challenge to the medical and scientific tradition in early modern France. Cambridge University Press, Cambridge.
22. Debus AG (1993) Paracelsus and the medical revolution of the renaissance; a 500th anniversary celebration. In: Debus AG (ed) Paracelsus, five hundred years; three american exhibits. National Library of Medicine, Washington, DC, p 3.
23. DiMaggio P (1997) Culture and cognition. Annu Rev Sociol 23: 263-288.
24. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development cost. J Health Econ 22: 151-185.
25. Downing GJ (2009) Key aspects of heath care on the path to personalized medicine. Transl Res 154: 272-276.
26. Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960-1964.
27. Ehrlich P ([1906] 1960) Address delivered at the dedication of the Georg-Speyer-Haus. In: Himmelweit F (ed) The collected papers of Paul Ehrlich. Pergamon Press, London, pp 53-63.
28. Fox Keller E (1992) Secrets of life, secrets of death: essays on language, gender and science. Routledge, New York.
29. Fox Keller E (1995) Refiguring life: metaphors of twentieth-century biology. Columbia University Press, New York.
30. Fox Keller E (2002) Making sense of life: explaining biological development with models, metaphors, and machines. Harvard University Press, Harvard.
31. Gabizon AA (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7: 243-254.
32. Galison P (1994) The ontology of the enemy: Norbert Wiener and the cybernetic vision. Crit Inq 21: 228-266.
33. Gaspar R (2013) Pushed off target with proteins. Nat Nanotechnol 8: 79-80.
34. Gatenby RA (2009) A change of strategy in the war on cancer. Nature 459: 508-509.
35. Gatenby RA, Brown J, Vincent T (2009) Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 69: 7499-7502.
36. Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Cancer Res 69: 4894-4903.
37. Gazeau F (2011) Interview by B. Bensaude Vincent, Université Paris-Diderot, 29 November 2011.
38. Gibson JJ (1979) The ecological approach to visual perception. Houghton Mifflin, Boston.
39. Goldacre B (2012) Bad Pharma: how drug companies mislead doctors and harm patients. Fourth Estate, London.
40. Harney J (2004) Nano weapons join the fight against cancer-"Nanoshells" and other tools of the ultrasmall realm could improve diagnosis and treatment of tumors. Technology Review, Retrieved May 11, 2012, from http://www. technologyreview. com/news/402690/nano-weapons-join-the-fight-against-cancer.
41. Harré R (2001) Dispositions and powers. In: Newton-Smith WH (ed) A companion to the philosophy of science. Blackwell Companions to Philosophy, Blackwell Publishers, Oxford, pp 97-101.
42. Harré R (2003) The materiality of instruments in a metaphysics for experiments. In: Radder H (ed) Philosophy of scientific experimentation. University of Pittsburgh Press, Pittsburgh, pp 19-38.
43. Henderson M (2009) New attack on cancer with nano-weapon. The Times, London, p 3.
44. Hillaireau H, Couvreur P (2009) Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66: 2873-2896.
45. Hoffman AS (2008) The origins and evolution of 'controlled' drug delivery systems. J Control Release 132: 153-163.
46. Hofmann B (2001) The technological invention of disease. Med Humanit 27: 10-19.
47. Holme NM, Fedotenko AI, Abegg D, Althaus J, Babel L, Favarger F, Reiter R, Tanasescu R, Zaffalon P-L, Ziegler A, Müller B, Saxer T, Zumbuehl A (2012) Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat Nanotechnol 7: 536-543.
48. Jain KK (2005) Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 4: 645-650.
49. Jain RK, Stylianopoulos T (2010) Delivering nanomedicines to solid tumors. Nat Rev Clin Oncol 11: 653-664.
50. Jones R (2004) Soft machines. Nanotechnology and life. Oxford University Press, Oxford.
51. Kain D (2008) "Smart Bomb" Nanoparticle strategy impact metastasis. UC San Diego News Center Letter. Retrieved August 10, 2012 from http://ucsdnews. ucsd. edu/newsrel/health/07-07SmartBomb. asp.
52. Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, Vural A, Pinarbasli O, Capan Y, Fernandez-Megia E, Novoa-Carballal R, Riguera R, Andrieux K, Couvreur P, Dalkara T (2009) A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 29: 13761-13769.
53. Kopf H (1975) Charakterisierung, anwendung und eignung der Nanokapsulierung auf acrylamidbasis, zur einhüllung niedermolekolarer arzneistoffe. Dissertation n° 5458, ETH Zürich.
54. Kopf H, Joshi RK, Soliva M, Speiser P (1976) Studium der Mizellpolymerisation in Gegenwart niedermolekularer Arzneistoffe. 1: Herstellung und Isolierung der Nanopartikel, Restmonomeren-bestimmung, physikalisch-chemische Daten. Pharm Ind 38: 281-284.
55. Kopf H, Joshi RK, Soliva M, Speiser P (1977) Studium der Mizellpolymerisation in Gegenwart niedermolekularer Arzneistoffe. 2: Bindungsart von inkorporierten niedermolekularen Modellarzneistoffen an Nanopartikel auf Polyacrylamid-Basis. Restmonomerenbestimmung, physikalisch-chemische Daten. Pharm Ind 39: 993-997.
56. Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, Ghosh K, Jurek S, Bencherif SA, Bhatta D, Coskun AU, Feldman CL, Wagner DD, Ingber DE (2012) Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 337: 738-742.
57. Kramer PA (1974) Albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci 63: 1646-1647.
58. Kwon IK, Lee SC, Han B, Park K (2012) Analysis of the current status of targeted drug delivery to tumors. J Control Release 164: 108-114.
59. Lakoff G, Johnson M (1980) Metaphors we live by. University of Chicago Press, Chicago.
60. Loeve S, Bensaude Vincent B, Gazeau F (2013) Nanomedicine metaphors: from war to care. Emergence of an oikological approach, NanoToday, Available online 9 September 2013, ISSN 1748-0132, http://dx. doi. org/10. 1016/j. nantod. 2013. 08. 003. (http://www. sciencedirect. com/science/article/pii/S1748013213000881).
61. Loeve S, Normand M (2011) How to trust a molecule? The case of cyclodextrins entering the nanorealm. In: Zülsdorf TB, Coenen C, Fiedeler U, Ferrari A, Milburn C, Wienroth M (eds) Quantum engagements. Social reflections of nanoscience and emerging technologies. IOS Press/AKA Verlag, Heidelberg, pp 195-217.
62. Maasen S, Weingart P (2000) Metaphors and the dynamics of knowledge. Routledge, London.
63. Manish G, Vimukta S (2011) Targeted drug delivery system: a review. Res J Chem Sci 1: 135-138.
64. Marty JJ (1977) The preparation, purification, and properties of nanoparticles. Dissertation, Victorian College of Pharmacy, Parksville, Australia.
65. Marty JJ, Oppenheim RC, Speiser P (1978) Nanoparticles-a new colloidal drug delivery system. Pharm Acta Helv 53: 17-23.
66. Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6: 924-935.
67. Montgomery SL (1991) Codes and combat in biomedical discourse. Sci Cult 2: 341-391.
68. Montgomery SL (1996) The scientific voice. Guilford Press, New York.
69. Morris MC (2012) Cancer et nanotechnologie. Innovation en diagnostic, vectorisation et thérapeutique. Rayonnement CNRS 58: 47-57.
70. Munos B (2009) Lessons for 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8: 959-968.
71. Nerlich B (2003) Tracking the fate of the metaphor 'Silent Spring' in British environmental discourse: Towards an evolutionary ecology of metaphor. Metaphorik. de, 04. Retrieved November 12, 2012 from http://www. metaphorik. de/04/nerlich. htm.
72. Nerlich B (2005) From Nautilus to Nanobo(a)ts: the visual construction of nanoscience. AZojono: J Nanotechnol Online. Retrieved January 28, 2012 from http://www. azonano. com/article. aspx?ArticleID=1466.
73. Nerlich B (2008) Powered by imagination: nanobots at the science photo library. Sci Cult 17: 269-292.
74. Nerlich B (2012) Biomilitarism and nanomedicine: Evil metaphors for the good of human health? Covalence. Retrieved May 26, 2012, from http://www. elca. org/What-We-Believe/Social-Issues/Faith-Science-and-Technology/Covalence/Features/Biomilitarism-and-nanomedicine. aspx.
75. Nordmann A (2004) Smart bombs against cancer cells: images of efficiency in NanoMedicine. (Paper presented at the Conference Nanotechnology and Smart Materials for Medical Applications: From Medical Diagnostic to Therapy, Rome, November 29-30). Retrieved Febreuary 16, 2012, from www. nanotec. it/nanomedicine/presentazioni/nordmann. pdf.
76. Norman DA (1990) The design of everyday things. Doubleday, New York.
77. Observatory NANO (2010) Focus report: nanotechnology and therapeutic delivery. Retrieved May 11, 2012, from http://www. observatorynano. eu/project/catalogue/2HM. FO/.
78. Observatory NANO (2012) Final Report. Retrieved May 11, 2012, from http://www. observatorynano. eu/project/document/3733/.
79. Park K (2007) Nanotechnology: what it can do for drug delivery. J Control Release 120: 1-3.
80. Patel P (2007) New nano weapon against cancer-gold nanoparticles with branching polymers could attack tumors in multiple ways. Technol Rev. Retrieved May 14, 2012, from http://www. technologyreview. com/news/408187/new-nano-weapon-against-cancer/.
81. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203-214.
82. Perez A (2008) Les nanomédicaments s'attaquent au cancer-Plusieurs projets de recherche français confirment l'intérêt scientifique et le potentiel thérapeutique des nanomédicaments. Les Echos, 20108, 17. Retrieved August 10, 2012, from http://archives. lesechos. fr/archives/2008/LesEchos/20108-78-ECH. htm.
83. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9: 1909-1915.
84. Pili B, Bourgaux C, Amenitsch H, Keller G, Lepêtre-Mouelhi S, Desmaële D, Couvreur P, Ollivon M (2010) Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study. Biochim Biophys Acta 1798: 1522-1532.
85. Pillai O, Dhanikula AB, Panchagnula R (2008) Drug delivery: an Odyssey of 100 years. Curr Opin Chem Biol 5: 439-446.
86. Rai MK, Deshmukh SD, Ingle AP, Gade AK (2012) Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J Appl Microbiol 112: 841-852.
87. Rasmussen A (2005) Préparer, produire, présenter des agents thérapeutiques. Histoires de l'objet médicament. In: Bonah C, Rasmussen A (eds) Histoire et médicament aux XIXe et XXe siècles. Éditions Glyphe, Paris, pp 159-188.
88. Rorty R (1979) Philosophy and the mirror of nature. Princeton University Press, Princeton.
89. Rossi MA (2012) Targeting anti-epileptic drug therapy without collateral damage: nanocarrier-based drug delivery. Epilepsy Currents 12: 199-200.
90. Sano K, Nakajima T, Choyke PL, Kobayashi H (2013) Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 7: 717-724.
91. Shakeri-Zadeh A, Ali Mansoori G, Reza Hashemian A, Eshghi H, Sazgarnia A, Reza Montazebadi A (2010) Cancerous cells targeting and destruction using folate conjugated gold nanoparticles. Dyn Biochem Process Biotechnol Mol Biol 4: 6-12.
92. Simondon G (1958) Du mode d'existence des objets techniques, 2nd edn. Aubier, Paris.
93. Singer E (2009) Stealthy nanoparticles attack cancer cells: drugs embedded in special polymers can more effectively shrink tumors. Technol Rev, Retrieved May 14, 2012, from http://www. technologyreview. com/business/23855/.
94. Strebhardt K, Ullrich A (2008) Timeline: Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8: 473-480.
95. Sumer B, Gao J (2008) Theranostic nanomedicine for cancer. Nanomedicine 3: 137-140.
96. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10: 507-519.
97. Te Kulve H, Rip A (2013) Societal and economic dimensions of nano-enabled drug delivery. Expert Opin Drug Deliv 10: 611-622.
98. Tiwari PM, Vig K, Dennis VA, Singh SR (2011) Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 1: 31-63.
99. Wagner V, Dullaart A, Bock A-K, Zweck A (2006) The emerging nanomedicine landscape. Nat Nanotechnol 24: 1211-1217.
100. Warner S (2004) Diagnostics plus therapy = theranostics. Scientist 18: 38-39.
101. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popović Z, Jain RK, Bawendi MG, Fukumura D (2011) Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci 108: 2426-2431.